Drug discontinuation: Lorlatinib Tablet (LORBRENA)
FDA lists 1 presentation as To Be Discontinued. Companies: Pfizer Inc..
- Published by source
- 2026-06-15
- First seen by Reality Radar
- 2026-10-22
- Last verified
- 2026-10-22
Affected
- Manufacturer
- Pfizer Inc.
- Products
- Lorlatinib Tablet LORBRENA
Whether your exact unit is affected depends on the model, serial number and region in the official notice.
What the official notice says
Risk: To Be Discontinued
Remedy / actions:
- Supply expected to exhaust 6/30/2026; NDC 0069-0227-01 25 mg; 30 tablets bottle with a child-resistant closure will continue to be manufactured; Discontinuation of the manufacture of this presentation
Is this affecting you?
Add what you own or use and Reality Radar will tell you when official changes match it — with evidence and next steps.
Sources
- openFDA Drug Shortages Tier A · official published 2026-06-15
Evidence ledger
Every piece of evidence we store is appended to a public hash chain, so later edits are detectable. Anyone can re-verify it.
| Entry | Kind | Observed | Evidence hash | Entry hash |
|---|---|---|---|---|
| #939 | new | 2026-10-22 | dc192c56c80f…2cf09b | 93d97e86cb18…fbb906 |
Chain head: #1094 edf3be25ec2e…478842